HQL, Longthera and Medicilon Form Collaboration to Co-Develop Novel anti-cancer drug targeting

04/18/2014, Longthera Pharmaceuticals, a pre-clinical stage biopharmaceutical company, based in Jiangsu Province, China, and HQL Pharmaceuticals, a drug discovery company utilizing its super power ChemSpace Scanner (CSS™) computational technology, based in Rehovot, Israel, announced that they have entered into a collaboration agreement for the development of anti cancer small-molecule drug candidate targeting the BCL-2 apoptotic pathway.

Under the terms of the agreement, HQL and Longthera will jointly continue the development of HQL’s anti-cancer apoptosis inducing program targeting the BCL-2 pathway.  Longthera will receive major part of commercial rights in China, while HQL retains the majority of the commercial rights outside of China. Medicilon, a leading pharmaceutical R&D outsourcing company in China, will provide discovery services for the program, including the development and testing of the drug candidate structural biology and initial pre-clinical development for both US FDA and CFDA IND filing.